1920px-hiv-budding-color

MSD trials long lasting PrEP implant for preventing HIV

July 23, 2019
Research and Development AIDS, HIV, MSD, PrEP, pharma

MSD is trialling an implant that prevents patients from contracting HIV, The Guardian has said. The US firm has tested …

dr_alvin_shih

Disarm Therapeutics hires Dr Alvin Shih as new President and CEO

July 23, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Massachusetts-based biotech Disarm Therapeutics has hired Dr Alvin Shih as their new President and CEO. The Cambridge, Mass.-based firm has …

takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous formulation of Entyvio smashes primary endpoint in Crohn’s disease

July 23, 2019
Manufacturing and Production, Research and Development Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma

Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the …

bug_plants_insect_leaf_nature_macrophotography_naturephotography_macro-1046343

Drug resistant malaria spreads in South East Asia

July 23, 2019
Manufacturing and Production South East Asia, global health, infectious diseases, malaria, parasites

Drug resistant malaria parasites are spreading rapidly in South East Asia, according to researchers from Thailand and the United Kingdom. …

FDA approves nine generic versions of Pfizer’s Lyrica

July 23, 2019
Manufacturing and Production, Sales and Marketing FDA, Lyrica, Pfizer, pharma

The FDA has given its approval to the first generic versions of Pfizer’s Lyrica (pregabalin), it has emerged, giving the …

schizophrenia

Acadia’s schizophrenia drug flops in Phase 3 trial

July 23, 2019
Manufacturing and Production acadia, clinical trials, menatl health, neuroscience, pharma, phase 3, schizophrenia

Acadia Pharmaceuticals has said its schizophrenia drug Nuplazid (primavanserin) has failed to beat placebo in a Phase 3 trial. Nuplazid …

gilead-sciences

Gilead buys Novartis’ herpes, flu and cold virus preclinical programmes

July 23, 2019
Manufacturing and Production Gilead, Novartis, antivrial, deal, herpes, influenza, rhinovirus

Gilead has acquired the rights to three of Novartis’ preclinical antiviral programmes, including investigational compounds with the potential to treat …

biohaven_enrolls_first_patient_in-97b6e9e792e571e7c1572873932fc7c0

FDA knocks back Biohaven’s ALS drug over manufacturing concerns

July 22, 2019
Sales and Marketing Biohaven, FDA, Nurtec, amyotrophic lateral sclerosis, pharma

Biohaven Pharmaceutical has seen its new therapy formulation for the treatment of amyotrophic lateral sclerosis (ALS) rejected by the FDA, …

nice_new_london_office_internal_2_8

NICE to review its decision making processes

July 22, 2019
Sales and Marketing Cost, NHS, NICE, UK, britain, pharma

Britain’s cost-effectiveness body NICE has said it will review the methods it uses to develop guidance on drugs, medical devices, …

celgene_building

Celgene’s Otezla becomes first and only FDA-approved therapy for oral ulcers in Behçet’s Disease

July 22, 2019
Sales and Marketing Behçet's disease, Behçet’s Disease, Celgene, apremilast, otezla, pharma

Celgene has revealed the US approval of Otezla (apremilast), confirming that the FDA awarded marketing authorisation for the treatment of …

450px-official_portrait_of_matt_hancock_crop_2

Government spend £9.2 billion on private healthcare providers for NHS in 2018-19

July 22, 2019
Sales and Marketing DHSC, NHS, UK, health, healthcare, politics, private providers

The Department of Health and Social Care paid £9.2 billion to private providers in the year prior to 31 March …

Ohio prosecutors file charges against opioid distributor Miami-Luken

July 22, 2019
Sales and Marketing US, USA, West Virginia, criminal case, opioid crisis, opioids

Federal prosecutors in Cincinnati have filed criminal charges against opioid distributor Miami-Luken, and four others, over the role they played …

mouse

Number of UK animal testing procedures falls to lowest level since 2007

July 19, 2019
Medical Communications, Research and Development Animal testing, UK, drug development, pharma, rresearch

A report from the Home Office of the UK Government has revealed that the prevalence of animal testing in the …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

July 19, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMAL Therapeutics, Alzheimer's Ebola, Amgen, AstraZeneca, EMA, FDA, Novartis, pharma

On 12 July news broke that Novartis, Amgen and Banner’s Alzheimer’s Institute were discontinuing a trial into investigational compound CNP520 …

novartis_outside_1

A decade after US approval, Novartis’ Gilenya scores marketing authorisation in China for relapsing multiple sclerosis

July 19, 2019
Medical Communications, Sales and Marketing Novartis, gilenya, multiple sclerosis, pharma

Novartis has revealed that its disease modifying drug Gilenya (fingolimod) has secured approval in China for the treatment of relapsing …

congo_forest

DRC rules out trialling experimental Ebola vaccines

July 19, 2019
Medical Communications Congo, DRC, Ebola, Ebola vaccine, pharma

The Democratic Republic of Congo (DRC) has said it will stick with Merck’s rVSV-ZEBOV ebola vaccine, as it ruled out …

Royal Pharmaceutical Society in Scotland says contingency plans do not mitigate risk of no-deal Brexit

July 19, 2019
Medical Communications RPS, brexit, no-deal Brexit, pharma, pharmaceuticals

The Royal Pharmaceutical Society (RPS) in Scotland has raised concerns that the Government’s contingency plans do not eliminate the risks …

johnmchutchison3x

Dr John McHutchinson steps down from Gilead with $1.1 million goodbye

July 18, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Gilead has said that Dr John McHutchison is stepping down after nine years at the firm. Gilead’s Chief Scientific Officer …

shutterstock_114045100

“Little to no progress” made in achieving gender representation within top pharma firms, report says

July 18, 2019
Manufacturing and Production, Medical Communications female representation, gender equality, pharma

The release of Women Count 2019, an annual report funded by The Pipeline, has revealed that “little to no progress” …

The Gateway to Local Adoption Series

Latest content